Emergent BioSolutions Announces R. Don Elsey, Chief Financial Officer, to Join Board of Directors of MdBio Foundation
ROCKVILLE, Md., Jan 11, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that R. Don Elsey, chief financial officer (CFO) and senior vice president of finance and administration, has joined the board of directors of the MdBio Foundation, a charitable and educational organization focused on supporting the State of Maryland's bioscience community through bioscience awareness, education and workforce development programs. MdBio Foundation is a subsidiary of the Tech Council of Maryland.
"It is my belief that the biopharmaceutical industry has the greatest potential to change and improve the quality of human life," said Elsey. "For this reason, I am both honored and excited to serve on the board of MdBio Foundation, an organization that is committed to nurturing life sciences in the service of the community."
"Don brings a wealth of industry experience and insight that will benefit MdBio Foundation and the constituents it serves," said Richard Zakour, Ph.D., Executive Director, MdBio. "We look forward to Don's service on the board as the foundation continues to grow its programs and increase its positive impact on the State of Maryland."
For the past 18 years, MdBio has been supporting the state's bioscience community through business development, advisory services, industry databases, industry reports and financial rewards. MdBio also provides an array of educational and workforce development programs, including speaker series, scholarships at Montgomery College, post-doctoral conference and career expo, the BioGENEius science competition, and summer science camps, including Governor's Academy on Biology and Young Explorers Program (UMBI). In addition, it operates the MdBioLab, a highly popular mobile bioscience laboratory in operation since 2003 that visits high schools throughout the state.
Elsey joined Emergent BioSolutions in 2005 and has served as chief financial officer since 2006. Prior to Emergent, Elsey held various finance positions at IGEN International, BioVeris Corporation, Applera, and International Business Machines, Inc. Elsey received an M.B.A. in finance and a B.A. in economics from Michigan State University. He is a certified management accountant.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at http://www.emergentbiosolutions.com/.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
[email protected]
or
Media:
Tracey Schmitt, 301-795-1800
Vice President, Corporate Communications
[email protected]